Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP versus TPF induction chemotherapy in stage III-IVA nasopharyngeal carcinoma
ChiCTR1900022288Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine, cisplatin, docetaxel and fluorouracil in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: 3-year failure-free survival. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
gemcitabinecisplatindocetaxelfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1900022288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022288.